JP2007506681A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007506681A5 JP2007506681A5 JP2006527166A JP2006527166A JP2007506681A5 JP 2007506681 A5 JP2007506681 A5 JP 2007506681A5 JP 2006527166 A JP2006527166 A JP 2006527166A JP 2006527166 A JP2006527166 A JP 2006527166A JP 2007506681 A5 JP2007506681 A5 JP 2007506681A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- use according
- medicament
- asthma
- daclizumab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090001123 antibodies Proteins 0.000 claims 12
- 102000004965 antibodies Human genes 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 8
- 208000006673 Asthma Diseases 0.000 claims 6
- 108010084740 Daclizumab Proteins 0.000 claims 5
- 229960002806 daclizumab Drugs 0.000 claims 5
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims 4
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 206010048594 Allergic granulomatous angiitis Diseases 0.000 claims 2
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010038683 Respiratory disease Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 201000009890 sinusitis Diseases 0.000 claims 2
- 229940092705 Beclomethasone Drugs 0.000 claims 1
- 229960004436 Budesonide Drugs 0.000 claims 1
- VOVIALXJUBGFJZ-VXKMTNQYSA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-VXKMTNQYSA-N 0.000 claims 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- XSFJVAJPIHIPKU-XWCQMRHXSA-N Flunisolide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O XSFJVAJPIHIPKU-XWCQMRHXSA-N 0.000 claims 1
- MGNNYOODZCAHBA-GQKYHHCASA-N Fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 1
- 229960001664 Mometasone Drugs 0.000 claims 1
- 229950008882 Polysorbate Drugs 0.000 claims 1
- 210000004241 Th2 Cells Anatomy 0.000 claims 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N Triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 claims 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 108091006028 chimera Proteins 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229960000676 flunisolide Drugs 0.000 claims 1
- 229960002714 fluticasone Drugs 0.000 claims 1
- 230000001404 mediated Effects 0.000 claims 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 230000002085 persistent Effects 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 239000008362 succinate buffer Substances 0.000 claims 1
- 229960005294 triamcinolone Drugs 0.000 claims 1
Claims (12)
- 呼吸器疾患の治療用医薬の調製における、特異的にIL-2受容体に結合する抗体の使用。
- 前記呼吸器疾患が、喘息、アレルギー性鼻炎、アトピー性皮膚炎、鼻ポリープ症、チャーグ・ストラウス症候群、副鼻腔炎及びCOPDから成る群から選定される、請求項１に記載の使用。
- 前記喘息が慢性、持続性喘息であり、及び／または前記喘息が中等度から重度の喘息である、請求項２に記載の使用。
- Th2-細胞を仲介したアレルギー性疾患の治療用医薬の調製における、特異的にIL-2受容体に結合する抗体の使用であって、前記疾患が、喘息、アレルギー性鼻炎、アトピー性皮膚炎、鼻ポリープ症、チャーグ・ストラウス症候群及び副鼻腔炎から成る群から選定される使用。
- 前記抗体がモノクローナル抗体、キメラ抗体、ヒト抗体またはヒト化抗体である、請求項１〜４のいずれか１項に記載の使用。
- 前記ヒト化抗体がダクリズマブである、請求項５に記載の使用。
- 前記抗体が、ダクリズマブと同一のエピトープと結合し、該抗体が任意にダクリズマブのアミノ酸配列と少なくとも80％同一であるアミノ酸配列を有し、更に該抗体が任意にダクリズマブのCDR領域のアミノ酸配列と少なくとも95％同一であるアミノ酸配列を有するCDR領域を有する、請求項１〜４のいずれか１項に記載の使用。
- 前記医薬が、非経口、静脈内、筋肉内、又は皮下で投与され、該医薬が任意に約100 mg/mlのダクリズマブ、約5.5から約6.5のpH、約0.01％から0.1％のポリソルベート、及び等張性に寄与する等張緩衝剤を有する、約20-60 mMのコハク酸塩緩衝剤を含む液剤である、請求項１〜３のいずれか１項に記載の使用。
- 前記医薬の治療有効量が約0.001 mg/kgから10 mg/kgであるか、または前記医薬の治療有効量が約0.5 mg/kgから4.0 mg/kgである、請求項１〜３のいずれか１項に記載の使用。
- 前記医薬の治療有効量が、約100 mgから200 mgで固定された投与量である、請求項１〜３のいずれか１項に記載の使用。
- 前記抗体が、前記ヒトIL-2受容体に少なくとも108M-1の結合親和性を有し、該抗体が、任意に前記ヒトIL-2受容体に少なくとも109M-1の結合親和性を有す、請求項１〜３のいずれか１項に記載の使用。
- 前記医薬が、ベクロメタゾン、ブデソニド、フルニソリド、フルチカゾン、トリアムシノロン、モメタゾン、及びアセトニドから成る群から選定される１つ以上の作用薬との組み合せにおいて投与される、請求項１〜３のいずれか１項に記載の使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50588303P | 2003-09-23 | 2003-09-23 | |
| US55297404P | 2004-03-12 | 2004-03-12 | |
| PCT/US2004/031640 WO2005030252A1 (en) | 2003-09-23 | 2004-09-21 | Treatment of respiratory diseases with anti-il-2 receptor antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007506681A JP2007506681A (ja) | 2007-03-22 |
| JP2007506681A5 true JP2007506681A5 (ja) | 2007-11-08 |
Family
ID=34396276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006527166A Pending JP2007506681A (ja) | 2003-09-23 | 2004-09-21 | 抗ｉｌ−２受容体抗体による呼吸器疾患の治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20050089517A1 (ja) |
| EP (1) | EP1675615A1 (ja) |
| JP (1) | JP2007506681A (ja) |
| AU (1) | AU2004275860A1 (ja) |
| BR (1) | BRPI0414688A (ja) |
| CA (1) | CA2538737A1 (ja) |
| RU (1) | RU2006113701A (ja) |
| WO (1) | WO2005030252A1 (ja) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3087991A1 (en) | 2003-11-08 | 2016-11-02 | Prothera Biologics | Composition of inter-alpha inhibitor proteins from human plasma for therapeutic use |
| CA2726281C (en) | 2008-05-28 | 2023-04-18 | Prothera Biologics, Llc | Preparation and composition of inter-alpha inhibitor proteins from blood |
| US20110236381A1 (en) * | 2008-12-10 | 2011-09-29 | Stavros Garantziotis | Inhibition of inter-alpha trypsin inhibitor for the treatment of airway disease |
| EP2710384B1 (en) * | 2011-05-12 | 2017-11-08 | Temple University - Of The Commonwealth System of Higher Education | Diagnosis and treatment of copd |
| US9572872B2 (en) | 2012-09-09 | 2017-02-21 | Prothera Biologics, Inc. | Treatment of disease using inter-alpha inhibitor proteins |
| CA3044416A1 (en) | 2016-12-13 | 2018-06-21 | Delinia, Inc. | Multivalent regulatory t cell modulators |
| EP3902584A4 (en) * | 2018-12-29 | 2022-09-07 | Kaleo, Inc. | DEVICES AND METHODS FOR DELIVERING SUBSTANCES IN A PRE-FILLED SYRINGE |
| WO2021066840A1 (en) * | 2019-10-04 | 2021-04-08 | R.P. Scherer Technologies, Llc | Anti-cd25 antibody-maytansine conjugates and methods of use thereof |
| CN118370816A (zh) * | 2024-03-22 | 2024-07-23 | 中日友好医院(中日友好临床医学研究所) | Il-2/抗il-2抗体免疫复合物的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4411993A (en) * | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| US4473493A (en) * | 1981-04-29 | 1984-09-25 | Immunex Corporation | Hybridoma antibody which inhibits interleukin 2 activity |
| US4845198A (en) * | 1984-05-21 | 1989-07-04 | Immunex Corporation | Hybridoma antibody which binds IL-2 receptor |
| US5336489A (en) * | 1985-09-05 | 1994-08-09 | The Beth Israel Hospital Association | Treatment of allograft rejection with IL-2 receptor-specific cytotoxins |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| AU8910891A (en) * | 1990-11-20 | 1992-06-11 | National Heart & Lung Institute, The | Treatment of lung diseases |
| EP1769819A3 (en) * | 1995-04-14 | 2013-05-22 | GlaxoSmithKline LLC | Metered dose inhaler for fluticasone propionate |
| US6013256A (en) * | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
| DE69937057T2 (de) * | 1998-07-27 | 2008-05-29 | Novartis Ag | Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen |
| WO2002081508A2 (en) * | 2001-04-06 | 2002-10-17 | University Of Bristol | Use of cd25 binding molecules in steroid-resistant patients |
| KR101329843B1 (ko) * | 2002-11-15 | 2013-11-14 | 젠맵 에이/에스 | Ｃｄ25에 대한 인간 모노클로날 항체 |
-
2004
- 2004-09-21 CA CA002538737A patent/CA2538737A1/en not_active Abandoned
- 2004-09-21 RU RU2006113701/15A patent/RU2006113701A/ru not_active Application Discontinuation
- 2004-09-21 BR BRPI0414688-3A patent/BRPI0414688A/pt not_active IP Right Cessation
- 2004-09-21 AU AU2004275860A patent/AU2004275860A1/en not_active Abandoned
- 2004-09-21 US US10/947,432 patent/US20050089517A1/en not_active Abandoned
- 2004-09-21 EP EP04785126A patent/EP1675615A1/en not_active Withdrawn
- 2004-09-21 WO PCT/US2004/031640 patent/WO2005030252A1/en active Application Filing
- 2004-09-21 JP JP2006527166A patent/JP2007506681A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102390714B1 (ko) | 벤랄리주맙을 이용하여 천식의 악화 속도를 감소시키는 방법 | |
| JP2015527364A5 (ja) | ||
| JP2017507139A5 (ja) | ||
| RU2015109716A (ru) | Способы лечения или предотвращения астмы посредством введения антагониста il-4r | |
| JP2007522229A5 (ja) | ||
| JP2009511480A5 (ja) | ||
| JP2006527193A5 (ja) | ||
| CA2569077A1 (en) | Combinations comprising antimuscarinic agents and corticosteroids | |
| JP2010521470A5 (ja) | ||
| JP2010500360A5 (ja) | ||
| JP2008511542A5 (ja) | ||
| CN107073114B (zh) | 使用瑞利珠单抗治疗中度到重度嗜酸细胞性哮喘 | |
| Seidling et al. | Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events | |
| Sengsayadeth et al. | Time to explore preventive and novel therapies for bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation | |
| JP2019528316A5 (ja) | ||
| JP2007506681A5 (ja) | ||
| KR102337601B1 (ko) | 벤랄리주맙을 이용하여 천식 증상을 개선시키는 방법 | |
| KR102337599B1 (ko) | 벤랄리주맙을 이용하여 천식 환자에서 강제 호기량을 증가시키는 방법 | |
| IL292706A (en) | Inhibition of type i interferon in systemic lupus erythematosus | |
| RU2006113701A (ru) | Лечение респираторных заболеваний антителами против рецептора il-2 | |
| JP2015511625A5 (ja) | ||
| JP2013525310A5 (ja) | ||
| JP2008110991A (ja) | 処置方法 | |
| JP2020504135A5 (ja) | ||
| JP2016534996A5 (ja) |